Sands Capital Ventures
Sands Capital is an investment manager who seeks to invest in technology and life sciences businesses from Series A through public listing..
Business Model: B2B
Revenue: $11M
Employees: 11-50
Rankings
Detailed Sands Capital Ventures Information
Geographic Data
Address: 1101 Wilson Blvd
City: Arlington
State: VA
Zip: 22209
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$837M
Social
Facebook
Linkedin
Crunchbase
Metrics
2,811,762Website Global Rank
6,109Website Monthly Traffic
Twitter Followers
Description
Sands Capital is an active, long-term investor in innovative growth businesses, globally. Our approach combines rigorous fundamental analysis with inspired thinking to seek high-quality businesses that are creating the future. We operate our business through two affiliates: Sands Capital Management, which focuses on investing in companies in public markets; and Sands Capital Ventures, which focuses on investing in companies in the private markets. By enabling our clients to participate in the growth of these businesses, our mission is to add value and enhance their wealth with prudence over time. An independent, staff-owned firm based in the Greater Washington, DC area, Sands Capital managed more than $75 billion USD in client assets as of December 31, 2020.
Contact Phone:
+17035624000
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 4/2019 | 908 Devices | Series E | 17.5M |
| 12/2012 | Stipple | Venture Round | 3M |
| 2/2020 | Globalization Partners | Private Equity Round | 0 |
| 10/2015 | Opinio | Series A | 7M |
| 2/2017 | Agilis Biotherapeutics | Venture Round | 12.7M |
| 10/2015 | Qvella Corporation | Series A | 20M |
| 12/2012 | Modernizing Medicine | Series B | 12M |
| 3/2023 | pgEdge | Seed Round | 9M |
| 10/2017 | BigBasket | Venture Round | 0 |
| 11/2021 | Upgrade | Series F | 0 |
| 8/2018 | Upgrade | Series C | 0 |
| 11/2015 | Quad Technologies | Series A | 3M |
| 5/2022 | LimaCharlie | Seed Round | 0 |
| 11/2021 | Mekonos | Series A | 0 |
| 9/2020 | Totient | Seed Round | 0 |
| 7/2021 | Wugen | Series B | 0 |
| 3/2017 | Blackbuck | Series C | 70M |
| 4/2019 | Brightflag | Series A | 7.9M |
| 4/2021 | Tellius | Series A | 8M |
| 9/2012 | Genometry | Series A | 3M |
| 1/2023 | HAWK:AI | Series B | 17M |
| 2/2022 | Speech Graphics | Series A | 7M |
| 2/2018 | BigBasket | Series E | 300M |
| 12/2020 | StockX | Series E | 275M |
| 2/2019 | Teckro | Series C | 0 |
| 9/2021 | HUNGRY | Series C | 0 |
| 2/2022 | Day Zero Diagnostics | Venture Round | 0 |
| 9/2020 | BYJU’S | Private Equity Round | 500M |
| 6/2016 | Kit Check | Series C | 0 |
| 1/2021 | Cytrellis Biosystems | Series C | 50M |
| 6/2021 | Primer | Series C | 0 |
| 3/2019 | PolyAI | Series A | 12M |
| 1/2017 | Funding Circle | Series F | 100M |
| 6/2022 | Papercup | Series A | 0 |
| 4/2021 | Biosplice Therapeutics | Venture Round | 0 |
| 11/2021 | SafeBreach | Series D | 0 |
| 9/2021 | Vesper | Venture Round | 0 |
| 11/2013 | Betable | Series A | 18.5M |
| 2/2022 | Red Sift | Series B | 0 |
| 8/2021 | Dice Therapeutics | Series C | 60M |
| 5/2022 | Redbud Brands | Venture Round | 0 |
| 9/2021 | Snyk | Series F | 304M |
| 2/2022 | SeLux Diagnostics | Series C | 0 |
| 9/2015 | Modernizing Medicine | Series E | 38M |
| 5/2019 | DoorDash | Series G | 600M |
| 8/2018 | Slack | Series H | 427M |
| 12/2019 | ArcherDX | Series C | 0 |
| 10/2018 | Acumen Pharmaceuticals | Series A | 15M |
| 1/2021 | Earli | Series A | 40M |
| 8/2020 | Qvella Corporation | Venture Round | - |
| 7/2016 | Scopely | Series B | 55M |
| 12/2020 | Papercup | Funding Round | 0 |
| 9/2022 | Vitara Biomedical | Series B | 0 |
| 11/2021 | Prilenia | Series B | 0 |
| 8/2017 | Day Zero Diagnostics | Seed Round | 3M |
| 4/2019 | Candel Therapeutics | Series C | 22.5M |
| 2/2018 | NepFin | Series A | 10M |
| 4/2015 | Funding Circle | Series E | 150M |
| 3/2019 | Karuna Therapeutics | Series B | 0 |
| 8/2010 | Complete Genomics | Series E | 39M |
| 4/2014 | Lending Club | Private Equity Round | 65M |
| 7/2021 | Exo | Series C | 0 |
| 2/2019 | Health Catalyst | Series F | 0 |
| 9/2021 | Qvella Corporation | Venture Round | - |
| 8/2017 | Uhnder | Series A | - |
| 7/2022 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series D | 0 |
| 5/2021 | Boom Entertainment | Series A | 0 |
| 10/2018 | Blackbuck | Series D | 27.5M |
| 3/2019 | Bridgit | Series A | 4.6M |
| 10/2021 | Bridgit | Series B | 0 |
| 6/2017 | Scopely | Series C | 60M |
| 2/2022 | Codoxo | Series B | 20M |
| 8/2021 | #Paid | Series B | 0 |
| 8/2020 | Freenome | Series C | 270M |
| 10/2018 | WireWheel.io | Series A | 10M |
| 9/2018 | Nanoview Biosciences | Series B | 10M |
| 4/2012 | Kidaptive | Seed Round | - |
| 8/2017 | Teckro | Series B | 10M |
| 12/2021 | Freenome | Series D | 300M |
| 11/2014 | Scopely | Series A | 35M |
| 7/2014 | AppDynamics | Series E | 70M |
| 10/2011 | Firefly BioWorks | Venture Round | 2M |
| 7/2020 | Thrive Earlier Detection | Series B | 0 |
| 9/2017 | BigBasket | Series E | 0 |
| 2/2021 | WireWheel.io | Series B | 20M |
| 10/2022 | Tellius | Series B | 0 |
| 9/2022 | RayzeBio | Series D | 160M |
| 1/2016 | Anaplan | Series E | 0 |
| 12/2018 | SeLux Diagnostics | Series B | 25M |
| 2/2020 | Spruce Biosciences | Series B | 88M |
| 9/2021 | JumpCloud | Series F | 0 |
| 5/2015 | MuleSoft | Series G | 0 |
| 7/2021 | Blackbuck | Series E | 0 |
| 5/2014 | Anaplan | Series D | 100M |
| 11/2020 | Acumen Pharmaceuticals | Series B | 0 |
| 7/2018 | Farcast | Series C | 40M |
| 4/2019 | HUNGRY | Series A | 0 |
| 5/2018 | Vesper | Series B | 23M |
| 5/2021 | Klaviyo | Series D | 320M |
| 7/2012 | Paydiant | Series B | 12M |
| 2/2019 | Health Catalyst | Debt Financing | 0 |
| 6/2016 | Bluesight | Series C | 20.4M |
| 1/2015 | Bluesight | Series B | 12M |
| 3/2017 | Upgrade | Series A | 0 |
| 6/2020 | Outreach | Series F | 50M |
| 9/2012 | Scopely | Seed Round | 8.5M |
| 12/2017 | Qvella Corporation | Series B | 0 |
| 3/2019 | Qvella Corporation | Venture Round | - |
| 9/2022 | Elephas | Series B | 41.5M |
| 9/2021 | Elephas | Series A | 20M |
| 1/2019 | Allvision | Seed Round | 3.2M |
| 5/2020 | Samsara | Series F | 700M |
| 1/2022 | Nucleix | Venture Round | 22M |
| 8/2020 | Taysha Gene Therapies | Series B | 0 |
| 6/2017 | Avitide | Equity | 12M |
| 1/2021 | Dice Therapeutics | Series C | 80M |
| 9/2021 | PolyAI | Series A | 14M |
| 8/2016 | Farcast | Series B | 27.4M |
| 11/2021 | Acrivon Therapeutics | Series B | 0 |
| 2/2021 | Personal Genome Diagnostics | Series C | 0 |
| 5/2021 | Lyra Health | Series F | 200M |
| 5/2022 | Credo AI | Series A | 0 |
| 7/2022 | Cleerly | Series C | 0 |
| 8/2021 | Gusto | Series E | 0 |
| 10/2019 | Scopely | Series D | 400M |
| 10/2020 | Scopely | Series E | 340M |
| 5/2015 | DocuSign | Series F | 0 |
| 12/2020 | Uhnder | Series C | 0 |
| 3/2014 | DocuSign | Series E | 85M |
| 3/2015 | Health Catalyst | Series D | 0 |
| 4/2019 | UiPath | Series D | 568M |
| 3/2016 | BigBasket | Series D | 150M |
| 11/2021 | SafeRide Health | Series B | - |
| 10/2011 | Zaarly | Series A | 14.2M |
| 12/2020 | Coagulo Medical Technologies | Venture Round | 6.5M |
| 11/2015 | AppDynamics | Series F | 0 |
| 6/2021 | Outreach | Series G | 0 |
| 7/2020 | Bridgit | Venture Round | 7M |
| 12/2020 | Brightflag | Equity | 28M |
| 6/2013 | Bluesight | Series A | 10.4M |
| 12/2022 | Snyk | Series G | 0 |
| 9/2019 | DataRobot | Series E | 206M |
| 11/2021 | Ankyra | Series B | 45M |
| 5/2019 | Blackbuck | Series D | 150M |
| 6/2021 | Nubank | Series G | 0 |
| 7/2022 | Cleerly | Series C | 0 |
| 7/2022 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series D | 0 |
| 6/2022 | Papercup | Series A | 0 |
| 5/2022 | LimaCharlie | Seed Round | 0 |
| 5/2022 | Redbud Brands | Venture Round | 0 |
| 5/2022 | Credo AI | Series A | 0 |
| 2/2022 | SeLux Diagnostics | Series C | 0 |
| 2/2022 | Red Sift | Series B | 0 |
| 2/2022 | Speech Graphics | Series A | 0 |
| 2/2022 | Day Zero Diagnostics | Venture Round | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
